UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DCD.C. 20549

_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

_____________________________________________________________________

Date of Report (Date of earliest event reported): February 4 2, 2026

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-11083

04-2695240

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234

(Address of ~~Principal~~principal ~~Executive~~executive ~~Offices~~offices) (Zip Code)

(508) 683-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value per share

BSX

New York Stock Exchange

0.625% Senior Notes due 2027

BSX27

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~ITEM~~Item 25.02~~. RESULTS~~ Departure OFof ~~OPERATIONS~~Directors ~~AND~~or ~~FINANCIAL~~Certain ~~CONDITION.~~Officers; Election of Directors; Appointment of Certain Officers;

OnCompensatory ~~February 4,~~Arrangements ~~2026, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025. A copy~~ of ~~the~~Certain ~~release is furnished with this report as Exhibit 99~~Officers.1.

~~The~~On ~~information~~February ~~contained~~2, in2026, ~~Item~~Yoshiaki ~~2.02~~Fujimori ofinformed ~~this~~Boston ~~Current~~Scientific ~~Report~~Corporation on(the ~~Form~~“Company”) 8that he will not stand for re-Kelection ~~and~~at ~~Exhibit~~the ~~99.1~~Company’s ~~shall~~2026 ~~not~~Annual beMeeting ~~deemed~~of Stockholders (the “~~filed~~2026 Annual Meeting”). ~~for~~Mr. ~~purposes~~Fujimori ofhas ~~Section~~served 18as a member of the ~~Securities~~Board ~~Exchange Act~~ of ~~1934~~Directors (the “~~Exchange Act~~Board”) orof ~~otherwise~~the ~~subject~~Company tosince July 2016 and currently serves as the ~~liabilities~~chair of ~~that~~the ~~section~~Risk, ~~nor~~Science ~~shall~~and itTechnology beCommittee. ~~deemed~~Mr. ~~incorporated~~Fujimori bywill ~~reference~~continue to serve as a director and in ~~any~~his ~~filing~~committee ~~under~~roles until the ~~Securities~~2026 ~~Act~~Annual ofMeeting. ~~1933~~Mr. orFujimori’s decision not to stand for re-election at the ~~Exchange~~2026 ~~Act,~~Annual ~~regardless~~Meeting ofis ~~any~~not ~~general~~the ~~incorporation~~result ~~language~~of inany ~~such~~disagreement ~~filing~~with the Company.

~~ITEM~~The 9Board and Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors to the Board following Mr.~~01. FINANCIAL~~ ~~STATEMENTS~~Fujimori’s ~~AND~~departure ~~EXHIBITS~~is in the best interest of the Company.

(d) Exhibits

Exhibit No. Description

99.1 Press Release issued by Boston Scientific Corporation dated February 4, 2026

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL

document

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the ~~Registrant~~registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	February 45, 2026	BOSTON SCIENTIFIC CORPORATION
		By:	/s/ Susan Thompson
			Susan Thompson
			Vice President, Chief Corporate Counsel and Assistant Secretary

Filing Compare · BOSTON SCIENTIFIC CORP